{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:34:59Z","timestamp":1787585699583,"version":"build-2736575974"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy, affecting motor, sensory, and autonomic function. Accurate assessment is important during treatment, when CIPN may necessitate dose\u00a0reductions or discontinuation, and after treatment, as chronic CIPN can greatly impact quality of life and safety in cancer survivorship. Measurement tools can include subjective measures, including clinician-based grading scales or patient-reported outcome measures (PROMs), and objective measures. This review aimed to summarize current CIPN assessment tools, highlighting characteristics such as feasibility, minimum clinically important differences (MCIDs), validity and reliability to allow for comparison and selection of tools by clinicians and researchers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following the Scale for the Assessment of Narrative Review Articles methodology guidelines, 2 investigators performed a comprehensive literature search using predefined search terms relating to CIPN measurement. Additional papers were identified through a search of prior systematic reviews and tracing back references from key articles. Data were extracted from source papers and any available appendices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 3 clinician-based grading scales, 20 PROMs, and 8 objective measurement tools. While the majority of tools have been validated for neuropathy, a minority of them have established MCIDs and validation in CIPN-specific populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tool selection should align with the specific needs of clinicians and researchers. Instruments that are valid, reliable, and assess multiple CIPN domains are recommended. Further research is needed to validate many of these tools in CIPN-specific populations and to determine their MCIDs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jncics\/pkaf119","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:07:14Z","timestamp":1766063234000},"source":"Crossref","is-referenced-by-count":5,"title":["Assessment tools for chemotherapy-induced peripheral neuropathy: a narrative review of clinician, patient-reported, and objective measures"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3911-9087","authenticated-orcid":false,"given":"Kaitlin","family":"Chen","sequence":"first","affiliation":[{"name":"Medical Physiology, Temerty Faculty of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2319-9348","authenticated-orcid":false,"given":"Eric","family":"Antonen","sequence":"additional","affiliation":[{"name":"Institute of Medical Sciences, Temerty Faculty of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]},{"name":"Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, University Health Network , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4372-3204","authenticated-orcid":false,"given":"Michelle B","family":"Nadler","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]},{"name":"Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Mauti","sequence":"additional","affiliation":[{"name":"Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, University Health Network , Toronto, ON,","place":["Canada"]},{"name":"Physical Medicine and Rehabilitation, Toronto Rehabilitation Institute, University Health Network , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8670-8514","authenticated-orcid":false,"given":"Jennifer M","family":"Jones","sequence":"additional","affiliation":[{"name":"Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, University Health Network , Toronto, ON,","place":["Canada"]},{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"2026011713311739300_pkaf119-B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci11010015","article-title":"Prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN) with non-pharmacological interventions: clinical recommendations from a systematic scoping review and an expert consensus process","volume":"11","author":"Klafke","year":"2023","journal-title":"Med Sci (Basel)"},{"key":"2026011713311739300_pkaf119-B2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.redox.2014.01.006","article-title":"Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy","volume":"2","author":"Areti","year":"2014","journal-title":"Redox Biol"},{"key":"2026011713311739300_pkaf119-B3","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"2026011713311739300_pkaf119-B4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fphar.2017.00086","article-title":"Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review","volume":"8","author":"Kerckhove","year":"2017","journal-title":"Front Pharmacol"},{"key":"2026011713311739300_pkaf119-B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rapm-2024-106229","article-title":"Global estimates of prevalence of chronic painful neuropathy among patients with chemotherapy-induced peripheral neuropathy: systematic review and meta-analysis of data from 28 countries, 2000\u201324","volume":"0","author":"D\u2019Souza","year":"2025","journal-title":"Reg Anesth Pain Med"},{"key":"2026011713311739300_pkaf119-B6","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1007\/s00520-021-06042-x","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin","volume":"29","author":"Maih\u00f6fner","year":"2021","journal-title":"Support Care Cancer"},{"key":"2026011713311739300_pkaf119-B7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11912-020-00903-0","article-title":"The physical consequences of chemotherapy-induced peripheral neuropathy","volume":"22","author":"Tofthagen","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"2026011713311739300_pkaf119-B8","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1007\/s00520-019-04771-8","article-title":"Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy","volume":"27","author":"Yeo","year":"2019","journal-title":"Support Care Cancer"},{"key":"2026011713311739300_pkaf119-B9","doi-asserted-by":"publisher","first-page":"151499","DOI":"10.1016\/j.soncn.2023.151499","article-title":"Real-life experiences of chemotherapy-induced peripheral neuropathy in patients with cancer: a qualitative meta-synthesis study","volume":"39","author":"Kim","year":"2023","journal-title":"Semin Oncol Nurs"},{"key":"2026011713311739300_pkaf119-B10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1001\/jamaneurol.2016.0383","article-title":"Chemotherapy induced peripheral neuropathy symptoms and fall risk","volume":"73","author":"Kolb","year":"2016","journal-title":"JAMA Neurol"},{"key":"2026011713311739300_pkaf119-B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"2026011713311739300_pkaf119-B12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Ann Oncol"},{"key":"2026011713311739300_pkaf119-B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JNCI","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2026011713311739300_pkaf119-B14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1&lt;207::aid-cncr2820470134&gt;3.0.co;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"2026011713311739300_pkaf119-B15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/07357909009017560","article-title":"Comprehensive criteria for assessing therapy-induced toxicity","volume":"8","author":"Ajani","year":"1990","journal-title":"Cancer Invest"},{"key":"2026011713311739300_pkaf119-B16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12955-020-01493-y","article-title":"Psychometric testing of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group\u2014Neurotoxicity (FACT\/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy","volume":"18","author":"Cheng","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2026011713311739300_pkaf119-B17","author":"FACT-GOG-NTX"},{"key":"2026011713311739300_pkaf119-B18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.6004\/jnccn.2022.7074","article-title":"Patient-reported outcome measures in chemotherapy-induced peripheral neurotoxicity: defining minimal and clinically important changes","volume":"21","author":"Li","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2026011713311739300_pkaf119-B19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"2026011713311739300_pkaf119-B20","doi-asserted-by":"publisher","first-page":"1073274818756608","DOI":"10.1177\/1073274818756608","article-title":"In search of a gold standard patient-reported outcome measure for use in chemotherapy-induced peripheral neuropathy clinical trials","volume":"25","author":"Smith","year":"2018","journal-title":"Cancer Control"},{"key":"2026011713311739300_pkaf119-B21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur J Cancer"},{"key":"2026011713311739300_pkaf119-B22","author":"Chemotherapy-Induced Peripheral Neuropathy"},{"key":"2026011713311739300_pkaf119-B23"},{"key":"2026011713311739300_pkaf119-B24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1186\/s12885-019-6113-3","article-title":"Development and validation of the Comprehensive Assessment Scale for Chemotherapy\u2013Induced Peripheral Neuropathy in survivors of cancer","volume":"19","author":"Kanda","year":"2019","journal-title":"BMC Cancer"},{"key":"2026011713311739300_pkaf119-B25","doi-asserted-by":"publisher","first-page":"100198","DOI":"10.1016\/j.apjon.2023.100198","article-title":"Randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: a quantitative study","volume":"10","author":"Kanda","year":"2023","journal-title":"Asia-Pac J Oncol Nurs"},{"key":"2026011713311739300_pkaf119-B26","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s00520-015-3032-y","article-title":"Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice","volume":"24","author":"Beijers","year":"2016","journal-title":"Support Care Cancer"},{"key":"2026011713311739300_pkaf119-B27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4143\/crt.2017.361","article-title":"Development and validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean patients with ovarian, fallopian tube, or primary peritoneal cancer","volume":"51","author":"Lee","year":"2019","journal-title":"Cancer Res Treat"},{"key":"2026011713311739300_pkaf119-B28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00520-015-2838-y","article-title":"Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study","volume":"24","author":"Gustafsson","year":"2016","journal-title":"Support Care Cancer"},{"key":"2026011713311739300_pkaf119-B29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1471-2407-5-116","article-title":"Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer","volume":"5","author":"Leonard","year":"2005","journal-title":"BMC Cancer"},{"key":"2026011713311739300_pkaf119-B30","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1007\/s00520-014-2275-3","article-title":"Evaluation of the Semmes\u2013Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy","volume":"22","author":"da Silva Sim\u00e3o","year":"2014","journal-title":"Support Care Cancer"},{"key":"2026011713311739300_pkaf119-B31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00520-011-1336-0","article-title":"Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients","volume":"20","author":"Driessen","year":"2012","journal-title":"Support Care Cancer"},{"key":"2026011713311739300_pkaf119-B32","doi-asserted-by":"publisher","first-page":"e14324","DOI":"10.7759\/cureus.14324","article-title":"Validation of the patient neurotoxicity questionnaire for patients suffering from chemotherapy-induced peripheral neuropathy in Greek","volume":"13","author":"Tsoleridis","year":"2021","journal-title":"Cureus"},{"key":"2026011713311739300_pkaf119-B33","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1097\/NCC.0b013e31820251de","article-title":"Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool","volume":"34","author":"Tofthagen","year":"2011","journal-title":"Cancer Nurs"},{"key":"2026011713311739300_pkaf119-B34","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jpain.2015.07.002","article-title":"Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the Treatment-induced Neuropathy Assessment Scale (TNAS)","volume":"16","author":"Mendoza","year":"2015","journal-title":"J Pain"},{"key":"2026011713311739300_pkaf119-B35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41687-020-0180-8","article-title":"The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment","volume":"4","author":"Mendoza","year":"2020","journal-title":"J Patient-Rep Outcomes"},{"key":"2026011713311739300_pkaf119-B36","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1016\/j.ejca.2013.04.004","article-title":"Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)","volume":"49","author":"Binda","year":"2013","journal-title":"Eur J Cancer"},{"key":"2026011713311739300_pkaf119-B37","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1186\/s12885-023-11541-7","article-title":"Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment\u2014oxaliplatin subscale: a prospective cohort study","volume":"23","author":"Gu","year":"2023","journal-title":"BMC Cancer"},{"key":"2026011713311739300_pkaf119-B38","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1188\/04.ONF.615-623","article-title":"Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study","volume":"31","author":"Almadrones","year":"2004","journal-title":"Oncol Nurs Forum"},{"key":"2026011713311739300_pkaf119-B39","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.jpainsymman.2008.05.013","article-title":"Development of a novel location-based assessment of sensory symptoms in cancer patients: preliminary reliability and validity assessment","volume":"37","author":"Burkey","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"2026011713311739300_pkaf119-B40","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ygyno.2021.08.022","article-title":"Development and validation of the Measure of Ovarian Symptoms and Treatment Concerns for Surveillance (MOST-S26): an instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment","volume":"163","author":"Campbell","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2026011713311739300_pkaf119-B41","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2169\/internalmedicine.54.3318","article-title":"Validity of the chemotherapy-induced peripheral neuropathy self-check sheet","volume":"54","author":"Miyoshi","year":"2015","journal-title":"Intern Med"},{"key":"2026011713311739300_pkaf119-B42","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11136-005-5370-6","article-title":"Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors","volume":"15","author":"Oldenburg","year":"2006","journal-title":"Qual Life Res"},{"key":"2026011713311739300_pkaf119-B43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/emj.18.3.205","article-title":"The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain","volume":"18","author":"Kelly","year":"2001","journal-title":"Emerg Med J EMJ"},{"key":"2026011713311739300_pkaf119-B44","doi-asserted-by":"publisher","first-page":"711691","DOI":"10.3389\/fnhum.2021.711691","article-title":"Commentary: the historical roots of visual analog scale in psychology as revealed by reference publication year spectroscopy","volume":"15","author":"Shiina","year":"2021","journal-title":"Front Hum Neurosci"},{"key":"2026011713311739300_pkaf119-B45","doi-asserted-by":"publisher","first-page":"2140420","DOI":"10.1155\/2018\/2140420","article-title":"An assessment of clinically important differences on the worst pain severity item of the modified brief pain inventory in patients with diabetic peripheral neuropathic pain","volume":"2018","author":"Marcus","year":"2018","journal-title":"Pain Res Manag"},{"key":"2026011713311739300_pkaf119-B46","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/ard.37.4.378","article-title":"Studies with pain rating scales","volume":"37","author":"Downie","year":"1978","journal-title":"Ann Rheum Dis"},{"key":"2026011713311739300_pkaf119-B47","doi-asserted-by":"publisher","first-page":"7828","DOI":"10.3390\/curroncol31120577","article-title":"Peripheral neuropathy instruments for individuals with cancer: a COSMIN-based systematic review of measurement properties","volume":"31","author":"Belloni","year":"2024","journal-title":"Curr Oncol"},{"key":"2026011713311739300_pkaf119-B48","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1007\/s11136-022-03154-7","article-title":"Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use","volume":"31","author":"Li","year":"2022","journal-title":"Qual Life Res"},{"key":"2026011713311739300_pkaf119-B49","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12885-019-5302-4","article-title":"Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy","volume":"19","author":"Molassiotis","year":"2019","journal-title":"BMC Cancer"},{"key":"2026011713311739300_pkaf119-B50","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00520-024-08878-5","article-title":"Exploring the reliability and validity of clinically-relevant outcome measures for chemotherapy-induced peripheral neuropathy","volume":"32","author":"Knoerl","year":"2024","journal-title":"Support Care Cancer"},{"key":"2026011713311739300_pkaf119-B51","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0363-5023(87)80049-7","article-title":"Reliability of two-point discrimination measurements","volume":"12","author":"Dellon","year":"1987","journal-title":"J Hand Surg"},{"key":"2026011713311739300_pkaf119-B52","doi-asserted-by":"publisher","first-page":"20361","DOI":"10.1038\/s41598-019-56969-9","article-title":"The relationship between evaluation methods for chemotherapy-induced peripheral neuropathy","volume":"9","author":"Yoshida","year":"2019","journal-title":"Sci Rep"},{"key":"2026011713311739300_pkaf119-B53","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1212\/WNL.0000000000012300","article-title":"Prospective evaluation of health care provider and patient assessments in chemotherapy-induced peripheral neurotoxicity","volume":"97","author":"Alberti","year":"2021","journal-title":"Neurology"},{"key":"2026011713311739300_pkaf119-B54","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1212\/WNL.53.8.1660","article-title":"Total neuropathy score: validation and reliability study","volume":"53","author":"Cornblath","year":"1999","journal-title":"Neurology"},{"key":"2026011713311739300_pkaf119-B55","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/TCRM.S360249","article-title":"Challenges in the early diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in adults: current perspectives","volume":"20","author":"van Doorn","year":"2024","journal-title":"Ther Clin Risk Manag"},{"key":"2026011713311739300_pkaf119-B56","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1212\/WNL.54.4.943","article-title":"Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies","volume":"54","author":"Merkies","year":"2000","journal-title":"Neurology"},{"key":"2026011713311739300_pkaf119-B57","doi-asserted-by":"publisher","first-page":"838302","DOI":"10.3389\/fneur.2022.838302","article-title":"Comparison of clinical symptoms and neurophysiological findings in patients with chemotherapy induced peripheral neuropathy","volume":"13","author":"Cho","year":"2022","journal-title":"Front Neurol"},{"key":"2026011713311739300_pkaf119-B58","doi-asserted-by":"publisher","first-page":"e1677","DOI":"10.1002\/cnr2.1677","article-title":"Assessment of chemotherapy-induced neurotoxicity using a point-of-care nerve conduction study device","volume":"6","author":"Jokim\u00e4ki","year":"2023","journal-title":"Cancer Rep"},{"key":"2026011713311739300_pkaf119-B59","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/jamainternmed.2024.2354","article-title":"Preventive effect of neuromuscular training on chemotherapy-induced neuropathy: a randomized clinical trial","volume":"184","author":"Streckmann","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026011713311739300_pkaf119-B60","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00482-015-0093-2","article-title":"Quantitative sensory testing (QST). English version","volume":"35","author":"M\u00fccke","year":"2021","journal-title":"Der Schmerz"},{"key":"2026011713311739300_pkaf119-B61","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1212\/01.WNL.0000058546.16985.11","article-title":"Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"60","author":"Shy","year":"2003","journal-title":"Neurology"},{"key":"2026011713311739300_pkaf119-B62","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10549-020-06079-2","article-title":"Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing","volume":"186","author":"Zhi","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2026011713311739300_pkaf119-B63","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40780-017-0089-4","article-title":"Objective evaluation of chemotherapy-induced peripheral neuropathy using quantitative pain measurement system (Pain Vision\u00ae), a pilot study","volume":"3","author":"Sato","year":"2017","journal-title":"J Pharm Health Care Sci"},{"key":"2026011713311739300_pkaf119-B64","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/ajco.13293","article-title":"A simple method of quantifying chemotherapy-induced peripheral neuropathy using PainVision PS-2100\u00ae","volume":"16","author":"Saito","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"2026011713311739300_pkaf119-B65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/0269215511412982","article-title":"Measures of sensation in neurological conditions: a systematic review","volume":"26","author":"Connell","year":"2012","journal-title":"Clin Rehabil"},{"key":"2026011713311739300_pkaf119-B66","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1007\/s00520-017-3772-y","article-title":"Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey","volume":"25","author":"McCrary","year":"2017","journal-title":"Support Care Cancer"},{"key":"2026011713311739300_pkaf119-B67","first-page":"715","article-title":"Monofilament assessment of neuropathy in a community diabetes clinic","volume":"92","author":"Rheeder","year":"2002","journal-title":"S Afr Med J"},{"key":"2026011713311739300_pkaf119-B68","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jocn.2017.05.018","article-title":"History of electromyography and nerve conduction studies: a tribute to the founding fathers","volume":"43","author":"Kazamel","year":"2017","journal-title":"J Clin Neurosci"},{"key":"2026011713311739300_pkaf119-B69","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1023\/A:1008344507482","article-title":"Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy","volume":"9","author":"Postma","year":"1998","journal-title":"Ann Oncol"},{"key":"2026011713311739300_pkaf119-B70","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1529-8027.2010.00292.x","article-title":"Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties","volume":"15","author":"Griffith","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"2026011713311739300_pkaf119-B71","doi-asserted-by":"publisher","first-page":"e2424139","DOI":"10.1001\/jamanetworkopen.2024.24139","article-title":"Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapy","volume":"7","author":"Li","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026011713311739300_pkaf119-B72","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/204946370800100203","article-title":"Cultural influences on pain","volume":"1","author":"Peacock","year":"2008","journal-title":"Rev Pain"},{"key":"2026011713311739300_pkaf119-B73","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ygyno.2015.11.011","article-title":"Chemotherapy-induced peripheral neuropathy: current status and progress","volume":"140","author":"Brewer","year":"2016","journal-title":"Gynecol Oncol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkaf119\/66049350\/pkaf119.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/1\/pkaf119\/66049350\/pkaf119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/1\/pkaf119\/66049350\/pkaf119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T18:31:25Z","timestamp":1768674685000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkaf119\/8385264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkaf119","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,19]]},"article-number":"pkaf119"}}